ALD - Alcoholic Liver Disease
Conditions
Brief summary
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose of the Clinical Core component of the P50 Northern Ohio Alcohol Center (NOAC) is to provide biological samples (plasma/serum, buffy coats, and urine) from patients with different stages of alcoholic liver disease, as well as healthy control subjects, to members of the NOAC. These samples can then be used to test specific hypotheses related to the presence of specific biomarkers in the serum, functional immune activity in PBMCs and/or genetic polymorphisms that may predict severity of disease, short- and long-term morbidity and mortality and/or responsivity to specific therapeutic interventions commonly used in clinical practice. This study is building on the established biorepositories and the diversity of outstanding clinical expertise at the Cleveland Clinic. This biorepository included clinical samples (plasma, serum, buffy coats, and urine) from patients with different stages of ALD and subjects who are heavy drinkers without ALD, recruited from the Cleveland Clinic alcohol use disorder treatment clinic. This study will be responsible for collecting more data to help build the CCF-ALD biorepository via subject recruitment and communication and specimen collection.
Interventions
OTHERBlood draw
Patients will have a one time blood draw
Sponsors
The Cleveland Clinic
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Alcoholic Steatosis Patients Inclusion * Fat accumulation (Steatosis) without signs of fibrosis/ inflammation in patients with alcohol abuse (alcohol intake \>60 g/day in men and \>40 g/day in women) * Abnormal liver serum tests indicative of liver disease (elevated AST\>ALT, y-glutamyl transpeptidase and bilirubin) . Alcoholic Hepatitis with Mild Fibrosis Inclusion * Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning) * Polymorphonuclear infiltrate * Fibrosis stage 1-2 Alcoholic Hepatitis with Advanced Fibrosis Inclusion * Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning) * Polymorphonuclear infiltrate * Fibrosis stage 3-4. Alcoholic Cirrhosis Inclusion * Fibrosis stage 4 * Presence of complications of cirrhosis such as esophageal varices with our without a previous episode of bleeding, splenomegaly, ascites, hepatic corroborate the diagnosis of cirrhosis. Alcoholic Cirrhosis with HCC Inclusion -Diagnostic criteria of cirrhosis and established HCC. The diagnosis of HCC will be established based on histological confirmation or contrast-enhanced radiographic imaging according to the AASLD recommendations. Exclusion * BMI\>35 * HBV * Hemochromatosis * Wilson's disease * Autoimmune hepatitis * Drug-inducted liver disease * Hepatitis C * Antitrypsin deficiency * Patients who do not sign informed consent. Non-alcoholic steatohepatitis Inclusion -Biopsy proven NASH and chronic liver disease due to HCV patients. Exclusion * Cancer * Diabetes * Hypertension * CAD or stroke * Past history of liver disease * Hepatitis C * Antitrypsin deficiency * Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks per week for men * BMI \>35. Healthy controls Inclusion -AUDIT-C score less than 4 in men and less than 3 in women. Exclusion * Cancer (except of non-melanoma skin cancer) * Diabetes * Hypertension * Hypercholesterolemia * Coronary artery disease or stroke * History of current or past liver disease of any etiology * BMI \>27Kg/m2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biorepository | This is a 5 year study | The goal of this study is to create a biorepository of samples from patients with different types of liver disease compared to each other and healthy controls |
Countries
United States
Contacts
Primary ContactAnnette Bellar, MSLA
Backup ContactRevathi Penumatsa, MD
Outcome results
None listed